Dr Jay Loeffler Joins Medical Advisory Board

RNS Number : 8089R

Advanced Oncotherapy PLC

31 October 2013

 



31 October 2013

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Appointment of World Authority on Proton Beam Therapy

Dr Jay Loeffler Joins Medical Advisory Board

Advanced Oncotherapy (AIM: AVO) announces the appointment of Dr Jay S Loeffler to its Medical Advisory Board, alongside Chairman Dr Nick Plowman, Senior Clinical Oncologist to St Bartholomew's Hospital and The Hospital for Sick Children Great Ormond Street, London,  Dr Margaret F Spittle, OBE, Department of Oncology, University College London Hospital and Professor Chris Nutting, Consultant Clinical Oncologist and Chair in Radiation Oncology at the Royal Marsden Hospital and The Institute of Cancer Research in London.

Jay Loeffler, M.D. is an honours graduate of Williams College and Brown University School of Medicine.  He trained in radiation oncology at the Harvard Joint Center and has been a faculty member at Harvard Medical School for 27 years.  He is currently the Herman and Joan Suit Professor of Radiation Oncology at Harvard Medical School and Chair of the Department of Radiation Oncology at the Massachusetts General Hospital.  

Dr Loeffler is a Member of the Institute of Medicine of the National Academies of Science.  He has spent his career investigating focal radiation delivery systems for tumours of the central nervous system.  Dr Loeffler is a world's authority on the use of proton therapy for benign, vascular and malignant brain tumours.

Advanced Oncotherapy's CEO, Dr Mike Sinclair, said,"This is a very important appointment for us.  Jay is perhaps the world's leading expert on focal radiotherapy treatment for tumours.  His colleagues on both the Medical Advisory Board and the Board of Advanced Oncotherapy are delighted that he has agreed to take up the appointment.  The executive team here and at ADAM at CERN in Geneva look forward to his input as we develop our technology to make proton therapy more widely available for cancer patients and their clinicians."

Dr Loeffler added: "I am honored to be involved with this exciting group of CERN trained investigators whose goal is to develop small, inexpensive accelerators for proton therapy. If the initial capital costs can be reduced, this important therapy will be available to many more patients at a markedly reduced cost."

For further information, please visit www.avoplc.com or contact:

Michael Sinclair, Chief Executive	Sandy Jamieson	Jon Levinson/ Lucy Williams	Simon Hudson
Advanced Oncotherapy Plc	Libertas Capital Corporate Finance Ltd	Peterhouse Corporate Finance	Tavistock Communications
	(NOMAD & Joint Broker)	(Joint Broker)	(Financial PR & IR)
[phone]	[phone]	[phone]	[phone]

 

About Advanced Oncotherapy Plc  

1.   AVO is a provider of radiotherapy services that harnesses the best in modern technology.  As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2.   AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT.  This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3.   AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT).  This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient.  It is currently available in the UK through Spire and other hospitals.

-ends-

 

END

 

 

MSCLLFVDIFLIVIV